TORONTO (Reuters) – Canada’s reliance on supply contracts to protected COVID-19 vaccines from drugmakers like Pfizer Inc has place each day everyday living for Canadians, and prospective clients for the economic climate more than the following calendar year, in the hands of a couple foreign firms struggling with frustrating world-wide desire.
As other governments pour hundreds of millions or billions into vaccine advancement, Canada has earmarked C$1 billion ($761 million) to invest in doses overseas. Meanwhile, Quebec-based Medicago has labored with a shoestring funds on its residence-grown, plant-centered vaccine.
Medicago, owned by Japan’s Mitsubishi Tanabe Pharma and tobacco enterprise Philip Morris, noted promising early trial knowledge this week and said on Thursday it options to commence large-scale scientific tests. The vaccine works by